Physician

Andrew D. Leavitt, M.D.

According to 2025 Medicare claims, Andrew Leavitt, M.D. (NPI: 1952343113) practices internal medicine in the Santa Rosa-Petaluma, CA market, with the plurality of this provider's patient population coming from Sonoma, CA. This provider's primary affiliated billing organization is UNIVERSITY OF CALIFORNIA - SAN FRANCISCO (NPI: 1285818112; TIN: 946036493) and primary practice location at 95311-9768.

Leavitt's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 357 traditional Medicare patients, billed 2,120,399 HCPCS/CPT codes, and received $4,399,022 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 334 prescription claims across 77 beneficiaries totaling $820,332 in drug costs, led by Promacta (Eltrombopag Olamine). Open Payments data shows 70 records totaling $655,356. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $3,646,209 and ending at $4,399,022. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $52,529 to $820,332. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	152	1,254	$3,646,209
2016	207	1,217	$2,876,479
2017	180	1,671,844	$2,626,732
2018	161	2,398,927	$2,364,558
2019	259	2,891,350	$3,105,189
2020	216	2,669,012	$3,278,000
2021	236	1,482,052	$2,553,699
2022	246	2,419,294	$3,765,989
2023	246	2,541,972	$4,756,763
2024	357	2,120,399	$4,399,022

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	13	83	$52,529
2016	28	137	$64,815
2017	32	141	$89,526
2018	34	149	$129,948
2019	39	240	$345,830
2020	45	232	$269,394
2021	50	235	$213,205
2022	58	242	$234,431
2023	70	285	$1,234,231
2024	77	334	$820,332

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	33	33	$151
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	125	202	$119
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	33	33	$115
99451	Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes	120	133	$31
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	45	69	$27

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Promacta	Eltrombopag Olamine	42	1,314	$597,636
Eliquis	Apixaban	122	7,724	$148,590
Xarelto	Rivaroxaban	48	3,150	$54,136
Tranexamic Acid	Tranexamic Acid	37	1,256	$14,631
Cyclosporine Modified	Cyclosporine, Modified	12	660	$2,511

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	34	$63,507	BioMarin Pharmaceutical Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	36	$591,849	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew D. Leavitt, M.D.?

Tedicare shows public-source Medicare data for Andrew D. Leavitt, M.D. (NPI 1952343113), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew D. Leavitt, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew D. Leavitt, M.D.?

Andrew D. Leavitt, M.D. is linked to UNIVERSITY OF CALIFORNIA - SAN FRANCISCO (billing NPI 1285818112) in the available physician profile data.

Does Andrew D. Leavitt, M.D. have Open Payments data?

Andrew D. Leavitt, M.D. has 70 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.